These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27630277)

  • 41. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer.
    Saadeh CE; Lee HS
    Ann Pharmacother; 2007 Apr; 41(4):606-13. PubMed ID: 17355997
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of cetuximab in the treatment of metastatic colorectal cancer.
    Holubec L; Liska V; Matejka VM; Fiala O; Dreslerova J; Mrazkova P; Treska V; Finek J
    Anticancer Res; 2012 Sep; 32(9):4007-11. PubMed ID: 22993351
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.
    Galizia G; Lieto E; De Vita F; Orditura M; Castellano P; Troiani T; Imperatore V; Ciardiello F
    Oncogene; 2007 May; 26(25):3654-60. PubMed ID: 17530019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New trends in epidermal growth factor receptor-directed monoclonal antibodies.
    Markman B; Capdevila J; Elez E; Tabernero J
    Immunotherapy; 2009 Nov; 1(6):965-82. PubMed ID: 20635913
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
    Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Anti-epidermal growth factor receptor monoclonal antibodies induced adverse events].
    Tsuji Y; Kogawa T; Abe M
    Gan To Kagaku Ryoho; 2010 May; 37(5):787-90. PubMed ID: 20495307
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
    Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
    J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution.
    Misale S; Di Nicolantonio F; Sartore-Bianchi A; Siena S; Bardelli A
    Cancer Discov; 2014 Nov; 4(11):1269-80. PubMed ID: 25293556
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
    Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
    J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic.
    Cohenuram M; Saif MW
    Anticancer Drugs; 2007 Jan; 18(1):7-15. PubMed ID: 17159497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
    Smith D; Bosacki C; Merrouche Y
    Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidermal growth factor receptor targeted therapies for solid tumours.
    Van den Eynde M; Baurain JF; Mazzeo F; Machiels JP
    Acta Clin Belg; 2011; 66(1):10-7. PubMed ID: 21485758
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab.
    Rodríguez J; Viúdez A; Ponz-Sarvisé M; Gil-Aldea I; Chopitea A; García-Foncillas J; Gil-Bazo I
    Crit Rev Oncol Hematol; 2010 Jun; 74(3):193-202. PubMed ID: 19700342
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Panitumumab following disease progression on cetuximab in patients with metastatic colorectal cancer: a retrospective review.
    Lau SC; Chung V; Lim D; Shibata S
    J Oncol Pharm Pract; 2014 Apr; 20(2):83-7. PubMed ID: 23353714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
    Fakih M
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1471-80. PubMed ID: 18759698
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
    Cohen RB
    Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cetuximab for colorectal cancer.
    Roila F; Garassino MC; Mantica C
    N Engl J Med; 2008 Mar; 358(11):1196; author reply 1196-7. PubMed ID: 18340662
    [No Abstract]   [Full Text] [Related]  

  • 60. Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with Immunotherapy in Metastatic Colorectal Cancer (mCRC).
    Xiong F; Zhou YW; Hao YT; Wei GX; Chen XR; Qiu M
    Expert Rev Gastroenterol Hepatol; 2024; 18(4-5):185-192. PubMed ID: 37705376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.